CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- PositionProfit margin is 51.6%, higher than 95% of its Biotechnology peers (median -47.7%)
- FinancialsAltman Z-Score 2.39: grey zone
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
884.18MUSDvs all stocks (USD)
Trailing P/E
16.38xvs Biotechnology peers
Revenue (TTM)
104.31MUSDvs all stocks (USD)
Profit Margin
51.58%vs Biotechnology peers
Beta
0.2450xvs all stocks
52-Week Change
18.02%vs all stocks
Market Capitalization
884.18MUSDvs all stocks (USD)
Enterprise Value
535.09MUSDvs all stocks (USD)
Trailing P/E
16.38xvs Biotechnology peers
Forward P/E
13.36xvs Biotechnology peers
PEG Ratio
-0.1487xvs Biotechnology peers
Price to Sales (TTM)
8.48xvs Biotechnology peers
Price to Book (MRQ)
3.05xvs Biotechnology peers
Enterprise to Revenue
5.13xvs Biotechnology peers
Enterprise to EBITDA
48.20xvs Biotechnology peers
Profit Margin
51.58%vs Biotechnology peers
Operating Margin
8.89%vs Biotechnology peers
Return on Assets (TTM)
1.33%vs Biotechnology peers
Return on Equity (TTM)
20.91%vs Biotechnology peers
Revenue (TTM)
104.31MUSDvs all stocks (USD)
Revenue per Share (TTM)
2.04USDUpdated Sep 28, 2026Quarterly Revenue Growth
-20.90%vs Biotechnology peers
Gross Profit (TTM)
78.30MUSDvs all stocks (USD)
EBITDA (TTM)
59.38MUSDvs all stocks (USD)
Net Income (TTM)
53.81MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-20.86%vs Biotechnology peers
Operating Cash Flow (TTM)
53.74MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
5.30MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
107.46MUSDFY2025 · Dec 31, 2025Operating Income
-3.60MUSDvs all stocks (USD)
Pre-tax Income
129.25MUSDFY2025 · Dec 31, 2025Income Tax Expense
23.35MUSDFY2025 · Dec 31, 2025Net Income
105.89MUSDFY2025 · Dec 31, 2025EBIT
131.71MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
59.38MUSDFY2025 · Dec 31, 2025Research & Development
37.41MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
73.65MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
10.17MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
2.46MUSDFY2025 · Dec 31, 2025EPS (Basic)
2.10USDFY2025 · Dec 31, 2025EPS (Diluted)
2.06USDFY2025 · Dec 31, 2025Basic Shares Outstanding
50.32MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
50.32MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
105.89MUSDFY2025 · Dec 31, 2025Operating Cash Flow
237.78MUSDFY2025 · Dec 31, 2025Free Cash Flow
237.74MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
168.64MUSDFY2025 · Dec 31, 2025Income Tax Paid
27.88MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
105.89MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.81MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-11.52MUSDFY2025 · Dec 31, 2025Stock-based Compensation
18.48MUSDFY2025 · Dec 31, 2025Other Non-cash Items
2.37MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-27.10MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
326.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
146.52MUSDFY2025 · Dec 31, 2025Capital Expenditures
-42.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-248.22MUSDFY2025 · Dec 31, 2025Sale of Investments
142.97MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-105.28MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-4.03MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-4.01MUSDFY2025 · Dec 31, 2025Shares Outstanding
51.89MSharesUpdated Sep 28, 2026Float Shares
25.87MSharesUpdated Sep 28, 2026Shares Short
1.69MSharesUpdated Sep 28, 2026Short Ratio
4.54daysvs all stocks
Short % of Shares Outstanding
5.18%vs all stocks
% Held by Insiders
4.61%vs all stocks
% Held by Institutions
94.71%vs all stocks
Total Cash (MRQ)
387.66MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
7.47USDUpdated Sep 28, 2026Total Debt (MRQ)
38.57MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1331xvs Biotechnology peers
Current Ratio (MRQ)
13.54xvs Biotechnology peers
Book Value per Share (MRQ)
5.58USDUpdated Sep 28, 2026Total Assets
485.57MUSDvs all stocks (USD)
Total Current Assets
418.46MUSDFY2025 · Dec 31, 2025Total Liabilities
188.85MUSDFY2025 · Dec 31, 2025Total Non-current Assets
67.11MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
150.54MUSDFY2025 · Dec 31, 2025Total Current Liabilities
38.30MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
167.81MUSDFY2025 · Dec 31, 2025Other Short-term Investments
147.55MUSDFY2025 · Dec 31, 2025Accounts Receivable
45.54MUSDFY2025 · Dec 31, 2025Accounts Payable
2.57MUSDFY2025 · Dec 31, 2025Short-term Debt
10.95MUSDFY2025 · Dec 31, 2025Long-term Debt
31.76MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
33.11MUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-859.63MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
296.72MUSDvs all stocks (USD)
52-Week Low
13.08USDUpdated Sep 28, 202652-Week High
21.03USDUpdated Sep 28, 202652-Week Change
18.02%vs all stocks
Beta
0.2450xvs all stocks
50-Day MA
16.97USDUpdated Sep 28, 2026200-Day MA
17.16USDUpdated Sep 28, 2026Avg 10-Day Volume
1.90MSharesUpdated Sep 28, 2026Avg 30-Day Volume
884.53KSharesUpdated Sep 28, 2026Diluted EPS (TTM)
1.04USDUpdated Sep 28, 2026Other Income / Expense
125.14MUSDFY2025 · Dec 31, 20254 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Cash Backing With OCF Coverage And Cash Near Total Debt
Cash on hand covers most or all of its total debt, and cash flow matches reported earnings.
Reads
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Profit margin is 51.6%, higher than 95% of its Biotechnology peers (median -47.7%)Significant
Profit margin: 0.52Industry median: -0.48Industry P95: 0.42Peers compared: 260
Financial Health
Altman Z-Score 2.39: grey zoneSignificant
Altman Z-Score: 2.39
High structural barrier to entryNotable
Barrier to Entry: 3.56
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Ardelyx Inc.
Tier 1ProductionApproval-Gated PipelineRule
Eis Eczacıbaşı İlaç ve Sanayi A.Ş.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Sana Biotechnology, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shenzhen YHLO Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cloudbreak Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hainan Haiyao Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Wanbangde Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hpgc Renmintongtai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Rigel Pharmaceuticals, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Guizhou Sanli Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
AngloGold Ashanti plc
4 interpretationsFCF Ratios ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingCash Backing With OCF Coverage And Cash Near Total Debt
Medpace Holdings Inc.
4 interpretationsFCF Ratios ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingCash Backing With OCF Coverage And Cash Near Total Debt
Pan American Silver Corp.
4 interpretationsFCF Ratios ElevatedCash-Flow Ratios ElevatedRevenue Growing With Receivables GrowingCash Backing With OCF Coverage And Cash Near Total Debt